Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

By sjmartinez • December 18, 2023

Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Dec;21(12):1281-1301. doi: 10.6004/jnccn.2023.0061. PMID: 38081133.

Tags: Hematology/Oncology, Publications

Structural Evaluations of a Selective Human STINGA230 Agonist and Its Use in Macrophage Immunotherapies

Tang Z, Zhao J, Li Y, Tomer S, Selvaraju M, Tien N, Sun D, Johnson DK, Zhen A, Li P, Wang J. Structural Evaluations of[...]

Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method

Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang YC, Li Z, Yu Y, Dunn[...]

Cracking the Genomic Code of CDK4/6 Inhibitor Resistance

Wander SA, Bardia A. Cracking the Genomic Code of CDK4/6 Inhibitor Resistance. Clin Cancer Res. 2024 May 15;30(10):2008-2010. doi: 10.1158/1078-0432.CCR-23-3413. PMID: 38319645.